Mandate

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

November 13, 2019 Capital Markets and Public M&A

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 125 million in issue proceeds.

The subscription price was determined to SEK 16 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates. 
Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Stephanie Stiernstedt.

 

Related

Vinge advises Stride.VC in connection with its investment in Anotherblock

In 2022, Anotherblock launched a blockchain-based marketplace for music rights. The company has through its platform granted fans access to streaming rights from several known artists. The investment round is led by Stride.VC.
May 25, 2023

Vinge advises M42 on its acquisition of Diaverum from Bridgepoint

Vinge is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of Diaverum AB.
May 22, 2023

Vinge advises Tele2 in connection with its notes issuance and tender offer

Vinge advises Tele2 AB (publ) in connection with its issuance of senior unsecured fixed rate notes in an amount of EUR 500 million and its parallel tender offer in respect of its previously issued notes due 2024.
May 22, 2023